Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...
OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...
A multiple sclerosis patient shares essential guidance from her 13-year diagnostic journey, offering hope and practical tips ...
ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.
An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...
Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...
Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...
cbc.ca on MSN8d
How AI is helping N.L. researchers sift through your health data — and come up with better treatmentsMemorial University researcher Michelle Ploughman says artificial intelligence can analyze health data in ways people can't, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback